← Back to Search

Intraocular Lens

enVista MX60EFH trifocal intraocular lens (IOL) for Cataract

N/A
Waitlist Available
Research Sponsored by Bausch & Lomb Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 120 to day 180 after second eye iol implantation
Awards & highlights

Summary

This trial is testing a new type of eye lens called the enVista trifocal intraocular lens. It is designed to help people see clearly at different distances after being implanted in the eye. The study focuses on patients who need a lens replacement, often due to cataracts.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 120 to day 180 after second eye iol implantation
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 120 to day 180 after second eye iol implantation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cumulative Rate of Secondary Surgical Interventions Due to the Optical Properties of the Lens
Photopic Uncorrected Distance Visual Acuity (UDVA) for First Implanted Eyes
Photopic Uncorrected Near and Intermediate Visual Acuity (UNVA and UIVA) for First Implanted Eyes at 40 cm and 66 cm, Respectively
+2 more
Secondary study objectives
Change From Baseline ( Preoperative ) in Uncorrected Photopic Near and Intermediate Visual Acuity (UNVA and UIVA) at 40 cm and 66 cm, Respectively, for First Implanted Eyes to Post-Operative Visit 4
IOL Rotation for All Eyes at Post-Operative Visit 4
Incidence of Subjects Experiencing at Least One Severe Visual Disturbance
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: enVista MX60EFH trifocal intraocular lens (IOL)Experimental Treatment1 Intervention
Group II: enVista MX60E monofocal intraocular lens (IOL)Active Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
enVista MX60EFH trifocal intraocular lenses (IOLs)
2020
N/A
~170

Find a Location

Who is running the clinical trial?

Bausch & Lomb IncorporatedLead Sponsor
255 Previous Clinical Trials
57,475 Total Patients Enrolled
48 Trials studying Cataract
15,918 Patients Enrolled for Cataract
Anya LoncaricStudy DirectorBausch & Lomb Incorporated
39 Previous Clinical Trials
20,498 Total Patients Enrolled
5 Trials studying Cataract
2,087 Patients Enrolled for Cataract
~30 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top